Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of p53 on the expression of combo induced dsRNAs in 2153L GEM tumors

ABSTRACT: Effect of p53 on the expression of combo induced dsRNAs in 2153L GEM tumors

PROVIDER: PRJNA1156765 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30559042_1.fastq.gz	Fastqsanger.gz
	SRR30559042_2.fastq.gz	Fastqsanger.gz
	SRR30559043_1.fastq.gz	Fastqsanger.gz
	SRR30559043_2.fastq.gz	Fastqsanger.gz
	SRR30559044_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Effect of p53 on the expression of combo induced dsRNAs in 2153L GEM tumors

Project description:We analyzed the expression of dsRNAs in control and p53 restored 2153L GEM tumors upon different treatments. Our ChIP-seq and RNA-seq experiments showed that the restored p53 bound to the regulatory regions of dsRNA-containing genes that account for 91% of the total dsRNA abundance in combination therapy–treated 2153L tumors, and suppressed their expression upon combination therapy. The abundance of dsRNA (TPM) was calculated from the dsRIP experiment.

2024-10-16 | GSE276354 | GEO

Gene expression profile at single cell level of immune cells from 2153L GEM tumors upon different treatments

Project description:To understand how the combination of ORIN1001 plus docetaxel promotes anti-tumor immunity, we performed single-cell RNA sequencing (scRNA-seq) of CD45+ cells from 2153L tumors. Our data found that combo induces CD8+ T cells that express high levels of T cell activation, cytotoxicity, and exhaustion genes. combo also increase the cDC1 and MHC-II high macrophages which exhibited higher M1-like macrophages scores.

2024-10-16 | GSE276356 | GEO

GEM-CESAR

Project description:GEM-CESAR

| PRJEB72353 | ENA

Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

Project description:Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

| PRJNA788281 | ENA

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling (Illumina)

Project description:Here we profile prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer Total RNA was isolated from established prostate cancers in 3 GEM models of prostate cancer - PB-MYC, Pten-/-, Pten-/- p53-/-

2015-02-20 | E-GEOD-61379 | biostudies-arrayexpress

Identifying actionable targets through integrative analyses of GEM model and human prostate cancer profiling [Agilent]

Project description:Here we prolife prostate cancers derived from GEM models of prostate cancer representative of human prostate cancer Total DNA was isolated from established prostate cancers in 4 GEM models of prostate cancer - PB-MYC, Pten-/-, Pten-/- p53-/-, Pten-/- Rosa26-ERG, and 3 cell lines derived from GEM models including CaP8, MYC CaP, and MPC3 and normalized to wild-type prostate of litter-mate mice of same genetic background strain

2015-02-20 | E-GEOD-61382 | biostudies-arrayexpress

p53 reactivation in liver tumors

Project description:We induced liver tumors by transforming liver progenitor cells (LPC) with retroviruses expressing oncogenic Ras coupled to tetracycline transactivator together with an inducible shRNA targeting p53. Transformed LPCs were orthotopical transplanted into recipient livers and after tumor onset mice were fed with either Doxycycline containing chow or normal chow. 8 days later tumors were harvested and RNA was extracted. RNA was extracted using Trizol. For microarray experiment, HrasV12 driven liver tumors harboring tet-off shp53 were treated with Doxycycline for 0 day (p53 OFF, as control) or 8 days (p53 ON). Samples were assessed by Affymetrix 430 2.0 mouse microarray.

2013-11-11 | E-GEOD-52091 | biostudies-arrayexpress

Gene expression of VPA and GEM

Project description:Background: Histone deacetylase (HDAC) is strongly associated with epigenetic regulation and carcinogenesis, and its inhibitors induce the differentiation or apoptosis of cancer cells. Valproic acid (VPA) is one of the clinically available HDAC inhibitors. We investigated the anticancer effects of VPA in combination with gemcitabine (GEM) in cholangiocarcinoma cell line, and explored the mechanisms of the anticancer effects using microarray analysis. Methods: A human cholangiocarcinoma cell line (HuCCT1) was used. The anticancer effects of VPA, or gemcitabine (GEM), and the effects of VPA combined with GEM, were studied by cell proliferation assay. The microarray analysis was performed, the genes were picked up using Gene Spring GX11.5, Ingenuity Pathways Analysis (IPA) was performed, and then the gene-expression was determined by RT-PCR. Results: GEM (5nM) and VPA (0.5mM) reduced by 23%, which significantly augmented the anticancer effect of GEM alone or VPA alone (P<0.01). Using the microarray analysis, forty-three genes were identified with the comparison between GEM group and GEM plus VPA combination group. The interactions were shown between genes of the “Cellular Development” relevant to the differentiation of cancer cell using IPA.

2011-02-09 | GSE27036 | GEO

RNAseq expression of p53-null and p53-null/PLK2-null mammary tumors

Project description:Bulk tumor samples from p53-null and p53-null/ PLK2-null tumors that have been serially transplanted in Balb/c mice

2022-03-28 | GSE174683 | GEO

RNAseq expression of p53-null and p53-null/PLK2-null mammary tumors

Project description:RNAseq expression of p53-null and p53-null/PLK2-null mammary tumors

| PRJNA731110 | ENA